Role Of Viruses In The Development Of Lung Disease In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,223,186.00
Summary
This study will investigate how lung disease starts in babies with cystic fibrosis and the role of viral infections in this process. The new knowledge gained will help us move towards treatments that prevent or delay the start of lung disease, something not currently possible. We believe this new treatment paradigm will lead to improved quality and extent of life of those with cystic fibrosis.
A POPULATION-BASED COHORT INVESTIGATION OF LUNG FUNCTION IN RELATION TO EARLY LIFE LOWER RESPIRATORY TRACT ILLNESS AND AEROALLERGN SENSITISATION
Funder
National Health and Medical Research Council
Funding Amount
$456,013.00
Summary
Infancy appears to be the critical developmental window during which important alterations in lung structure and function develop. In this study we will assess how early lung function evolves in relation to potential insults such as lower respiratory tract infections and allergic inflammation. These are the mechanisms by which asthma is thought to develop. We will use exciting new lung function tests to evaluate lung function abnormalities associated with peripheral dysfunction characteristic of ....Infancy appears to be the critical developmental window during which important alterations in lung structure and function develop. In this study we will assess how early lung function evolves in relation to potential insults such as lower respiratory tract infections and allergic inflammation. These are the mechanisms by which asthma is thought to develop. We will use exciting new lung function tests to evaluate lung function abnormalities associated with peripheral dysfunction characteristic of chronic airway disease such as asthma.Read moreRead less
Long Term Outcomes Of Infant Lung Function In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$509,456.00
Summary
We have shown that babies with cystic fibrosis (CF) who are apparently well can still have lung problems. As lung disease is the major cause of death in CF we need ways to monitor the condition in babies, identify those at greatest risk of lung changes and predict which children should receive newer treatments. We have developed a unique program for the measurement of lung function in babies. We now aim to find out the long term consequences of lung function changes detected in infants with CF.
High Flow Cannula Therapy In Bronchiolitis, A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,283,342.00
Summary
Bronchiolitis is the leading cause of paediatric hospitalisation in Australia. Despite multiple research studies the outcome has not changed. Our recent studies supported by other international studies have shown that the use of high flow nasal cannula oxygen may reduce the severity and prevent progression of the disease. We aim to investigate if HFNC in regional hospitals can reduce the number of infants transferred to specialist children’s hospitals and reduce the socio-economic burden.
Bronchopulmonary Dysplasia – A Regenerative Medicine Approach
Funder
National Health and Medical Research Council
Funding Amount
$480,406.00
Summary
Bronchopulmonary dysplasia is a major leading cause of morbidity and mortality in premature babies. There is no cure. We have previously shown that amnion epithelial cells can reduce the extent of lung damage during early stages of lung development. We aim to understand how amnion cells can promote repair by interacting with existing cell types in order to restore normal lung structure and function. The outcomes from this study will help design clinical trials and develop new therapies.
Amniotic Exosomes - Nanomedicine For Bronchopulmonary Dysplasia
Funder
National Health and Medical Research Council
Funding Amount
$647,058.00
Summary
Extremely premature babies are at serious risk of developing a life threatening chronic lung disease known as bronchopulmonary dysplasia. This is expensive to treat and even babies who survive often end up with lifelong complications. Our team believes that nanoparticles released by placental stem cells have the ability to reverse the disease and that this can be administered without complex medical tools so that parents can administer it themselves after discharge.
A Multi-centre, Double-blind, Randomised Controlled Trial To Evaluate The Efficacy Of 10 Valent-pneumococcal-Protein D Conjugate Vaccine In Reducing Respiratory Exacerbations In Children Aged ? 18 Months With Suppurative Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,160,660.00
Summary
Chronic suppurative (ie infected) lung diseases in children are major causes of poor health and deaths worldwide. Repeated childhood infections contribute to poor lung health in adults. The most common organism causing infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi can reduce repeated respiratory infections in children. If so, vaccination may lead to substantial improvements in current/ future lung health, and considerable dir ....Chronic suppurative (ie infected) lung diseases in children are major causes of poor health and deaths worldwide. Repeated childhood infections contribute to poor lung health in adults. The most common organism causing infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi can reduce repeated respiratory infections in children. If so, vaccination may lead to substantial improvements in current/ future lung health, and considerable direct and indirect cost of disease savings.Read moreRead less
Characterization Of Cellular Inflammatory Responses Underlying Acute Viral Bronchiolitis In Infants
Funder
National Health and Medical Research Council
Funding Amount
$583,224.00
Summary
This project seeks to characterize the inflammatory mechanisms triggered during severe respiratory virus infections that result in hospitalization of infants. These are associated with later development of asthma. We aim to identify new molecular targets for anti-inflammatory drug development, with the long term goals of improving treatment for acute disease, and prevention of subsequent asthma.
Human Amnion Epithelial Cell Therapy For Bronchopulmonary Dyspliasa
Funder
National Health and Medical Research Council
Funding Amount
$1,048,035.00
Summary
Preterm infants, especially those born very early, commonly develop a type of chronic lung disease called bronchopulmonary displasia (BPD). There is currently no cure or means of preventing BPD. Cells from the amniotic membrane that surrounds the developing baby before birth show promise as a treatment, or perhaps even a way of preventing, BPD. This project will use a preterm lamb model of BPD to assess the ability of amnion cells to treat or prevent the disease.
Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.